Outcome of kidney function after ischaemic and zero-ischaemic laparoscopic and open nephron-sparing surgery for renal cell cancer
Nephron-sparing surgery (NSS) remains gold standard for the treatment of localised renal cell cancer (RCC), even in the case of a normal contralateral kidney.02/08/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 8, 2019 Category: Urology & Nephrology Source Type: news
Comparative study of renal cell carcinoma in patients less than 40 years of age and older age patients: A retrospective single-center study
Renal cell carcinoma (RCC) is typically found in the older age group between 50 and 70 years of age. However, diagnosis of renal cancer is increasing more rapidly in patients less than 40 years if age compared to older age patients.02/06/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 6, 2019 Category: Urology & Nephrology Source Type: news
Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study
Targeted therapy (TT) has improved survival for metastatic renal cell carcinoma (mRCC). However, survival is usually limited if brain metastases (BMs) develop.02/06/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 6, 2019 Category: Urology & Nephrology Source Type: news
First-Line TKIs Less Effective in Non-Clear-Cell Renal Cell Carcinoma
According to a study that was published in Urologic Oncology, patients with metastatic non-clear-cell renal cell carcinoma (nccRCC) have worse outcomes from first-line therapy with tyrosine kinase inhibitors (TKIs) than patients with metastatic clear-cell RCC (ccRCC).01/31/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 31, 2019 Category: Urology & Nephrology Source Type: news
Personalized Vaccine to be Tested in Patients with Kidney Cancer
Researchers at the Dana-Farber Cancer Institute are working to develop a vaccine for the treatment of renal cell cancer.01/30/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 30, 2019 Category: Urology & Nephrology Source Type: news
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial
Sunitinib is administered on a rigid schedule that may not be optimal for all patients. We hypothesised that toxicity-driven dose and schedule changes would optimise drug exposure and outcome for each patient.01/29/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 29, 2019 Category: Urology & Nephrology Source Type: news
Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer
This study evaluates whether sunitinib and pazopanib treatments are associated with change in skeletal muscle area (SMA) and total lean body mass (LBM) as well as to compare their efficacies and safety profiles in patients with metastatic renal cell cancer (mRCC).01/29/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 29, 2019 Category: Urology & Nephrology Source Type: news
Obesity Factors May Increase Kidney Cancer Risk
According to recent research conducted by Spectrum Health, certain factors such as diastolic blood pressure and fasting insulin were found to be associated with renal cell carcinoma.01/28/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 28, 2019 Category: Urology & Nephrology Source Type: news
Cutaneous metastasis of renal cell carcinoma: Fine needle aspiration provides rapid diagnosis
The diagnosis of cutaneous metastasis of renal cell carcinoma is challenging in a young person in absence of a prior history of cancer. In such situation, fine needle aspiration alone as a minimally invasive procedure can provide rapid, accurate and cost effective diagnosis, even in case of unknown primary.01/23/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 23, 2019 Category: Urology & Nephrology Source Type: news
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
In the ongoing phase 3, CheckMate 214 trial, nivolumab plus ipilimumab improved overall survival compared with sunitinib in patients with intermediate or poor risk, previously untreated, advanced renal cell carcinoma.01/23/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 23, 2019 Category: Urology & Nephrology Source Type: news
New study identifies specific obesity-related risk factors for kidney cancer
(Spectrum Health) A new study confirms the long-suspected role of obesity as a risk factor for developing renal cell carcinoma (RCC), a type of kidney cancer, and identifies several specific obesity-related factors. These factors include multiple measures of obesity, diastolic blood pressure and fasting insulin. In contrast, the study found little evidence for an association with RCC risk for systolic blood pressure, circulating lipids, diabetes or fasting glucose. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 17, 2019 Category: Cancer & Oncology Source Type: news
Immunotherapy/VEGF Inhibitor Combos to Define Frontline Standard in mRCC
VEGF TKIs have long defined the frontline standard of care in metastatic renal cell carcinoma (mRCC), but several promising trials evaluating their use in combination with immunotherapy agents may redefine the frontline setting in this patient population.01/15/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 15, 2019 Category: Urology & Nephrology Source Type: news
European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
Yesterday, Bristol-Myers Squibb announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg ( “low-dose”) for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC).01/15/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 15, 2019 Category: Urology & Nephrology Source Type: news
European Commission approves Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) for first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma
Bristol-Myers Squibb Company (NYSE: BMY) announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg ("low-dose") for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC). (Source: World Pharma News)
Source: World Pharma News - January 15, 2019 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news
Royal Jelly May Ease Adverse Effects of RCC Drug Therapy
Royal jelly, a substance secreted by worker honeybees that is the exclusive food for queen bees, may ease the adverse effects of tyrosine kinase inhibitor (TKI) therapy for advanced renal cell carcinoma (RCC).01/11/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 11, 2019 Category: Urology & Nephrology Source Type: news
